Intervention With Omega-3 in Children With Attention Deficit Hyperactivity Disorder(ADHD)
Key facts
- Who runs it
- University Hospital of North Norway
- Where
- Norway2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 332 people enrolled
- Started
- 3 Nov 2017
- Ended
- 20 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Calanus oil
- Medical Paraffin
- Record updated
- 22 June 2025
Who can take part
- Age
- 6 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- ADHD according to DSM-IV criteria
Who cannot take part
- ADHD medication
- infantil autism, psychosis, bipolar disorders and serious somatic disease
- IQ below 70
- any abnormal or pathological blood test during trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to determine if marine monounsaturated and polyunsaturated fatty acids can benefit children aged 6-16 years with ADHD and related symptoms. It is a randomized, double-blind, placebo-controlled study involving approximately 330 children from Norway. The study will assess ADHD symptoms reported by caregivers, teachers, and the child at baseline, after 6 months of treatment, and 6 months post-treatment. Secondary outcomes will include reading and writing difficulties, cognitive functions, and physical health.
The 2 groups in the trial
- Calanus oilExisting treatment, for comparison
Children receiving omega-3 in form om calanus oil in capsule form
- PlaceboPlacebo, for comparison
Children receiving medical paraffin in capsule form (2 ml volume per day)
Treatment: Medical Paraffin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ADHD and Nutrition: The Influence of Omega-3 on ADHD Related Symptoms
- Publications
- Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.The Cochrane database of systematic reviews, 2023
- Record updated
- 22 June 2025